QUICKLINKS AND VIEW OPITONS
European drug agency recommends sales of Acomplia be stopped in Europe because of risks
Thursday, October 23, 2008 12:13 pm Email this article
The “benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union" according to a recommendation by the European Medicines Agency (EMEA) to French drugmaker Sanofi Aventis on October 23rd, 2008.
The European Medicines Agency is based in London and regulates treatments in the 27 nations of the European Union.
The EMEA has determined that Acomplia doubles the risk of psychiatric disorders such as anxiety, depression, panic attacks and "suicidal ideation".
The drug has been taken by more than 700,000 people worldwide.
Acomplia was linked to 5 deaths and 720 adverse drug reactions in Britain in the past two years according to a report in June 2008.
The drug has never been approved for sale in the U.S., but has been available in the EU since June 2006.
Because of this, it is likely that it will never be approved for sale in the U.S.
Capell, K. Sanofi Aventis Pulls Acomplia From European Market BusinessWeek, 2008 Oct 23.
Kelley T. Sanofi’s acomplia for obesity gets `death knell’ from eu agency. Bloombergcom. 2008 Oct 23.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.